-
1 Comment
Chembio Diagnostics, Inc is currently in a long term downtrend where the price is trading 44.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Chembio Diagnostics, Inc's total revenue rose by 19.8% to $8M since the same quarter in the previous year.
Its net income has dropped by 83.6% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 61.6% to $-6M since the same quarter in the previous year.
Based on the above factors, Chembio Diagnostics, Inc gets an overall score of 2/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US1635722093 |
Sector | Healthcare |
Industry | Diagnostics & Research |
Market Cap | 17M |
---|---|
PE Ratio | None |
Target Price | 8 |
Dividend Yield | 0.0% |
Beta | 1.86 |
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID 19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, NEXT GENERATION DPP, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York. As of April 27, 2023, Chembio Diagnostics, Inc. operates as a subsidiary of Biosynex SA.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CEMI using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025